Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the quarter and year ended December 31, 2021, and provided updates on its ophthalmology pipeline. “Ocular has had another strong quarter and a productive year,” said Antony Mattessich, President and Chief Executive Officer. “Our comme